Based on the ORIC PHARMAC.INC.DL-0001 stock forecast from 0 analysts, the average analyst target price for ORIC PHARMAC.INC.DL-0001 is not available over the next 12 months. ORIC PHARMAC.INC.DL-0001’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ORIC PHARMAC.INC.DL-0001 is Neutral, which is based on 2 positive signals and 2 negative signals. At the last closing, ORIC PHARMAC.INC.DL-0001’s stock price was EUR 7.85. ORIC PHARMAC.INC.DL-0001’s stock price has changed by +0.64% over the past week, -15.59% over the past month and -1.26% over the last year.
No recent analyst target price found for ORIC PHARMAC.INC.DL-0001
No recent average analyst rating found for ORIC PHARMAC.INC.DL-0001
Company Overview ORIC PHARMAC.INC.DL-0001
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Read Less
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible ...Read More
Frequently Asked Questions About ORIC PHARMAC.INC.DL-0001 (4TZ:F) Stock
Stock Target Advisor's fundamental analysis for ORIC PHARMAC.INC.DL-0001's stock is Neutral.
Unfortunately we do not have enough data on 4TZ:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4TZ:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4TZ:F's stock to indicate if its overvalued.
The last closing price of 4TZ:F's stock was EUR 7.85.
The most recent market capitalization for 4TZ:F is EUR 0.57B.
Unfortunately we do not have enough analyst data on 4TZ:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ORIC PHARMAC.INC.DL-0001's stock.
As per our most recent records ORIC PHARMAC.INC.DL-0001 has 112 Employees.
ORIC PHARMAC.INC.DL-0001's registered address is 240 East Grand Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from ORIC PHARMAC.INC.DL-0001's website at https://www.oricpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ORIC PHARMAC.INC.DL-0001 (4TZ:F) Stock
Stock Target Advisor's fundamental analysis for ORIC PHARMAC.INC.DL-0001's stock is Neutral.
Unfortunately we do not have enough data on 4TZ:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4TZ:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4TZ:F's stock to indicate if its overvalued.
The last closing price of 4TZ:F's stock was EUR 7.85.
The most recent market capitalization for 4TZ:F is EUR 0.57B.
Unfortunately we do not have enough analyst data on 4TZ:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ORIC PHARMAC.INC.DL-0001's stock.
As per our most recent records ORIC PHARMAC.INC.DL-0001 has 112 Employees.
ORIC PHARMAC.INC.DL-0001's registered address is 240 East Grand Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from ORIC PHARMAC.INC.DL-0001's website at https://www.oricpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4TZ:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
